MGF (Mechano Growth Factor) vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | MGF (Mechano Growth Factor) | Teriparatide |
|---|---|---|
| Dose Range | 400 mcg–1.2 mg | 20 mcg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 4–6 weeks | 52–104 weeks |
| Route | intramuscular | subcutaneous |
| Mechanism | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
MGF (Mechano Growth Factor), Teriparatide are both commonly used for:
Key Differences
Unique to MGF (Mechano Growth Factor):
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | MGF (Mechano Growth Factor) | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
MGF (Mechano Growth Factor)
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Acta biochimica et biophysica Sinica, 2023
- Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia.
International immunopharmacology, 2021
- Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity.
Experimental neurology, 2020
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?